S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20

Nurix Therapeutics Stock Forecast, Price & News

+0.73 (+2.70%)
(As of 12/6/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
196,213 shs
Average Volume
412,427 shs
Market Capitalization
$1.24 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Nurix Therapeutics logo

About Nurix Therapeutics

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.


Nurix Shares Gain On Encouraging Early Data From Blood Cancer Trial
October 28, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$17.82 million
Book Value
$7.47 per share


Net Income
$-43.24 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.24 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.20 out of 5 stars

Medical Sector

395th out of 1,390 stocks

Pharmaceutical Preparations Industry

176th out of 673 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Nurix Therapeutics (NASDAQ:NRIX) Frequently Asked Questions

Is Nurix Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Nurix Therapeutics stock.
View analyst ratings for Nurix Therapeutics
or view top-rated stocks.

When is Nurix Therapeutics' next earnings date?

Nurix Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Nurix Therapeutics

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its earnings results on Thursday, October, 14th. The company reported ($0.65) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.02. The business earned $10.25 million during the quarter, compared to analysts' expectations of $8.73 million. Nurix Therapeutics had a negative net margin of 342.27% and a negative trailing twelve-month return on equity of 29.81%.
View Nurix Therapeutics' earnings history

What price target have analysts set for NRIX?

7 analysts have issued 12-month price targets for Nurix Therapeutics' stock. Their forecasts range from $42.00 to $64.00. On average, they anticipate Nurix Therapeutics' share price to reach $53.17 in the next twelve months. This suggests a possible upside of 91.5% from the stock's current price.
View analysts' price targets for Nurix Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Nurix Therapeutics' key executives?

Nurix Therapeutics' management team includes the following people:
  • Dr. Arthur T. Sands, CEO, Pres & Director (Age 59, Pay $852.77k)
  • Dr. Gwenn Hansen Ph.D., Chief Scientific Officer (Age 50, Pay $673.85k)
  • Dr. Christine Ring, Gen. Counsel & Sec. (Age 56, Pay $548.45k) (LinkedIn Profile)
  • Dr. John Kuriyan, Founder & Member of Scientific Advisory Board
  • Dr. Michael Rapé Ph.D., Founder & Member of Scientific Advisory Board
  • Prof. Arthur Weiss, Founder & Member of Scientific Advisory Board
  • Mr. Johannes Van Houte, Chief Financial Officer (Age 55)
  • Mr. Howard A. Simon J.D., Esq., SPHR, VP of Operations & Corp. Counsel (Age 62)
  • Rita Kwong, Sr. Accounting Mang.
  • Ms. Daisy Chhokar, VP of HR

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR).

When did Nurix Therapeutics IPO?

(NRIX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.

What is Nurix Therapeutics' stock symbol?

Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX."

Who are Nurix Therapeutics' major shareholders?

Nurix Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.57%), TRV GP Iii LLC (5.43%), Wellington Management Group LLP (2.75%), Wasatch Advisors Inc. (2.63%), EcoR1 Capital LLC (2.53%) and Geode Capital Management LLC (1.41%). Company insiders that own Nurix Therapeutics stock include Christine Ring, Gwenn Hansen, Houte Hans Van and Pierre Beaurang.
View institutional ownership trends for Nurix Therapeutics

Which major investors are selling Nurix Therapeutics stock?

NRIX stock was sold by a variety of institutional investors in the last quarter, including TRV GP Iii LLC, EcoR1 Capital LLC, Morgan Stanley, Millennium Management LLC, Wellington Management Group LLP, Goldman Sachs Group Inc., Ponoi Management LLC, and Ponoi II Management LLC. Company insiders that have sold Nurix Therapeutics company stock in the last year include Christine Ring, Gwenn Hansen, Houte Hans Van, and Pierre Beaurang.
View insider buying and selling activity for Nurix Therapeutics
or view top insider-selling stocks.

Which major investors are buying Nurix Therapeutics stock?

NRIX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Clough Capital Partners L P, WestHill Financial Advisors Inc., Geode Capital Management LLC, Alliancebernstein L.P., Candriam Luxembourg S.C.A., Mariner LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Nurix Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Nurix Therapeutics?

Shares of NRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nurix Therapeutics' stock price today?

One share of NRIX stock can currently be purchased for approximately $27.76.

How much money does Nurix Therapeutics make?

Nurix Therapeutics has a market capitalization of $1.24 billion and generates $17.82 million in revenue each year. The company earns $-43.24 million in net income (profit) each year or ($2.39) on an earnings per share basis.

How many employees does Nurix Therapeutics have?

Nurix Therapeutics employs 2,020 workers across the globe.

What is Nurix Therapeutics' official website?

The official website for Nurix Therapeutics is www.nurixtx.com.

How can I contact Nurix Therapeutics?

The company can be reached via phone at 415-660-5320 or via email at [email protected].

This page was last updated on 12/7/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.